Caliman Leonardo Pandolfi, Tavares Rubens Lene Carvalho, Piedade Josiane Barbosa, DE Assis Ana Carolina Silvano Couto, DE Jesus Dias DA Cunha Karen, Braga Letícia DA Conceição, Silva Luciana Maria, DA Silva Filho Agnaldo Lopes
Department of Obstetrics and Gynecology, Faculty of Medicine, Federal University of Minas Gerais (UFMG), 30130-100.
Oncol Lett. 2012 Sep;4(3):556-560. doi: 10.3892/ol.2012.776. Epub 2012 Jun 27.
The function of microsatellite instability (MSI) and the optimal panel of markers for epithelial ovarian cancer (EOC) are not well established. This study aimed to use the National Cancer Institute (NCI) markers BAT25, BAT26, D2S123, D5S346 and D17S250 to evaluate MSI in patients with ovarian serous cystadenocarcinoma, compared with ovarian serous cystadenoma and normal ovaries. A total of 37 patients were divided into three groups, as follows: cystadenocarcinoma (n=13), cystadenoma (n=10) and normal ovaries (n=14). DNA was extracted with TRIzol and quantified by spectrophotometry. MSI was evaluated by polymerase chain reaction (PCR), and classified as high (MSI-H), low (MSI-L) or stable (MSS). FIGO staging was I/II in 23.1% and III/IV in 76.9% of the cystadenocarcinoma group. Polymorphisms were found using at least one marker in 32 women, and were observed with D2S123 (83.7%), D17S250 (81.1%), D5S346 (72.9%), BAT25 (21.6%) and BAT26 (16.2%) markers. In the cystadenocarcinoma group, BAT25, BAT26, D2S123, D5S346 and D17S250 markers were positive in 30.8, 76.9, 53.8, 69.2 and 69.2% of patients, respectively. The same markers were positive in 30, 50, 40, 60 and 30% of the cystadenoma group, and 50, 71.4, 71.4, 64.3 and 63.3% in the normal ovary group, respectively. MSI-H was present in 84.6, 60 and 78.6% of the cystadenocarcinoma, cystadenoma and normal patients, respectively. MSI-L was detected in 0, 30 and 7.1%, and MSS was identified in 15.4, 10 and 14.3% of the cystadenocarcinoma, cystadenoma and normal patients, respectively. The frequency of MSI in both benign epithelial ovarian neoplasms and in normal ovaries was high, as well as in EOC, with no statistically significant difference between the groups. This suggests that MSI may arise as a consequence of the ovulatory process, and not solely as a feature of malignant ovarian tumors.
微卫星不稳定性（MSI）的功能以及上皮性卵巢癌（EOC）的最佳标志物组合尚未完全明确。本研究旨在使用美国国立癌症研究所（NCI）的标志物BAT25、BAT26、D2S123、D5S346和D17S250来评估卵巢浆液性囊腺癌患者的MSI，并与卵巢浆液性囊腺瘤和正常卵巢进行比较。总共37例患者被分为三组，如下：囊腺癌组（n = 13）、囊腺瘤组（n = 10）和正常卵巢组（n = 14）。用TRIzol提取DNA并通过分光光度法定量。通过聚合酶链反应（PCR）评估MSI，并分为高（MSI-H）、低（MSI-L）或稳定（MSS）。在囊腺癌组中，23.1%为FIGO I/II期，76.9%为III/IV期。在32名女性中使用至少一种标志物发现了多态性，D2S123（83.7%）、D17S250（81.1%）、D5S346（72.9%）、BAT25（21.6%）和BAT26（16.2%）标志物出现多态性。在囊腺癌组中，BAT25、BAT26、D2S123、D5S346和D17S250标志物阳性患者分别为30.8%、76.9%、53.8%、69.2%和69.2%。在囊腺瘤组中，相同标志物阳性患者分别为30%、50%、40%、60%和30%，在正常卵巢组中分别为50%、71.4%、71.4%、64.3%和63.3%。MSI-H分别在84.6%的囊腺癌患者、60%的囊腺瘤患者和78.6%的正常患者中存在。MSI-L在囊腺癌、囊腺瘤和正常患者中的检测率分别为0、30%和7.1%，MSS分别为15.4%、10%和14.3%。良性上皮性卵巢肿瘤和正常卵巢以及EOC中MSI的频率都很高，各组之间无统计学显著差异。这表明MSI可能是排卵过程的结果，而不仅仅是恶性卵巢肿瘤的特征。
